Related references
Note: Only part of the references are listed.Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201
J. Mora et al.
ANNALS OF ONCOLOGY (2021)
Review of nonopioid multimodal analgesia for surgical and trauma patients
Stephy George et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2020)
Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
D. A. Morgenstern et al.
ANNALS OF ONCOLOGY (2020)
The importance of early identification of infusion-related reactions to monoclonal antibodies
Macarena C. Caceres et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
Drug-Induced Pseudoallergy: A Review of the Causes and Mechanisms
Bo Zhang et al.
PHARMACOLOGY (2018)
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931
M. Fevzi Ozkaynak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Naloxone dosage for opioid reversal: current evidence and clinical implications
Rachael Rzasa Lynn et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2018)
Overview and recent advances in the treatment of neuroblastoma
Sarah B. Whittle et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Anti-GD2 immunotherapy for neuroblastoma
Sameer Sait et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival
Irene Y. Cheung et al.
ONCOIMMUNOLOGY (2017)
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials
Wendy B. London et al.
CANCER (2017)
Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG)
Margaret J. Zhou et al.
EUROPEAN JOURNAL OF CANCER (2015)
Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology
Wenyong Tong et al.
PLOS ONE (2015)
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
Nai-Kong V. Cheung et al.
ONCOIMMUNOLOGY (2012)
Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two
B. A. Baldo et al.
ANAESTHESIA AND INTENSIVE CARE (2012)
ANTI-GD2 STRATEGY IN THE TREATMENT OF NEUROBLASTOMA
R. K. Yang et al.
DRUGS OF THE FUTURE (2010)
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
Linda S. Sorkin et al.
PAIN (2010)
Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine
Joe Brierley et al.
CRITICAL CARE MEDICINE (2009)
Ketamine use for reduction of opioid tolerance in a 5-year-old girl with end-stage abdominal neuroblastoma
DL Anghelescu et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2005)
Share Paper
